Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zanamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 7/20 | 0.72 |
| ▸ | NEU3 | Q9UQ49 | 5/20 | 0.70 |
| ▸ | NEU4 | Q8WWR8 | 5/20 | 0.70 |
| ▸ | NEU1 | Q99519 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zanamivir SCHEMBL456058 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL13459831 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL13693731 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL13980833 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL15448958 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL12367840 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL13169991 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL14080017 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL3497032 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL496815 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-7527934-B2 | Labeled substrate conjugates for identifying enzyme inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | NEU2 4315/4885NEU3 3534/4885NEU4 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.